Submissions from 2022
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)., Sasha Stanton, Lisa Diana MacDonald, Staci Mellinger, Nikki Moxon, Tracy L. Kelly, Heather Ann Hirsch, Stephan Fiset, Kristina H Young, and David B Page
646 Neoadjuvant immunotherapy combining maveropepimut-S (MVP-S) with letrozole decreases Ki67 and increases Th1 immune response in hormone receptor positive (HR+) early-stage breast cancer (ESBC), Sasha Stanton, David Page, Kristina Young, and See all authors in comments
Abstract PR007: Candidate antigens for a ductal carcinoma in situ vaccine, essential for breast cancer cell survival across multiple subtypes, are immunogenic in DCIS and IBC, Sasha Stanton, Jason Schlumbohm, and Mary L. Disis
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC), Sasha Stanton and See all authors in comments
Phase I trial of the safety and immunogenicity of a tri-antigen vaccine targeting HER2, IGFBP-2, and IGF-IR in patients with non-metastatic breast cancer, Sasha Stanton and See all authors in comments
3380 / 8 - Seven autoantibody panel, validated in two independent patient serum collections, can detect women with DCIS and invasive breast cancer, Sasha Stanton and See full list of authors in comments
Neoadjuvant survivin-targeted immunotherapy maveropepimut-S (MVP-S) to increase Th1 immune response in Ki67-high hormone receptor-positive (HR+) early-stage breast cancer (ESBC)., Sasha Stanton, Kristina H Young, David B Page, and See all authors in comments
Immunology 101, SE Stanton
647 Phase I studies of AgenT-797, a novel allogeneic invariant natural killer T (iNKT) cell therapy, for the treatment of patients with solid tumors or multiple myeloma, Don Stevens, Rachel Sanborn, and See all authors in comments
Risk factors for reduced function in women with a history of breast cancer., Nicholas Stoyles, Andrea Cheville, David S Zucker, Blair Richards, Mary Vargo, Lynn Gerber, Samman Shahpar, Maryanne Henderson, Gina Jay, and Sean R Smith
Malignant Pilomatricoma of the Lower Extremity: A Difficult and Rare Diagnosis., Chaitra Subramanyam, Paige Dyrek, Xu Yao, and Martin H Kay
Blockade of interleukin 10 potentiates antitumour immune function in human colorectal cancer liver metastases., Kevin M Sullivan, Xiuyun Jiang, Prajna Guha, Christopher Lausted, Jason A Carter, Cynthia Hsu, Kevin P Labadie, Karan Kohli, Heidi L Kenerson, Sara K Daniel, Xiaowei Yan, Changting Meng, Arezou Abbasi, Marina Chan, Y David Seo, James O Park, Ian Nicholas Crispe, Raymond S Yeung, Teresa S Kim, Taranjit S Gujral, Qiang Tian, Steven C Katz, and Venu G Pillarisetty
Health-related quality-of-life analyses from a multicenter, randomized, double-blind phase 2 study of patients with differentiated thyroid cancer treated with lenvatinib 18 or 24 mg/day., Matthew H. Taylor, Sophie Leboulleux, Yury Panaseykin, Bhavana Konda, Christelle de La Fouchardiere, Brett G M Hughes, Andrew G Gianoukakis, Young Joo Park, Ilia Romanov, Monika K Krzyzanowska, Diana Garbinsky, Bintu Sherif, Jie Janice Pan, Terri A Binder, Nicholas Sauter, Ran Xie, and Marcia S Brose
IO in Thyroid Cancer, Michael Taylor
SL-Cloud: A Cloud-based resource to support synthetic lethal interaction discovery., Bahar Tercan, Guangrong Qin, Taek-Kyun Kim, Boris Aguilar, John Phan, William Longabaugh, David Pot, Christopher J Kemp, Nyasha Chambwe, and Ilya Shmulevich
Survival with Cemiplimab in Recurrent Cervical Cancer., Krishnansu S Tewari, Bradley J Monk, Ignace Vergote, Austin Miller, Andreia C de Melo, Hee-Seung Kim, Yong Man Kim, Alla Lisyanskaya, Vanessa Samouëlian, Domenica Lorusso, Fernanda Damian, Chih-Long Chang, Evgeniy A Gotovkin, Shunji Takahashi, Daniella Ramone, Joanna Pikiel, Beata Maćkowiak-Matejczyk, Eva M Guerra Alía, Nicoletta Colombo, Yulia Makarova, Danny Rischin, Stephanie Lheureux, Kosei Hasegawa, Keiichi Fujiwara, Jingjin Li, Shaheda Jamil, Vladimir Jankovic, Chieh-I Chen, Frank Seebach, David M Weinreich, George D Yancopoulos, Israel Lowy, Melissa Mathias, Matthew G Fury, Ana Oaknin, and Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9
TP022/#1424 A phase I/II study evaluating intraperitoneal GEN-1 in combination with neoadjuvant chemotherapy in patients newly diagnosed with advanced epithelial ovarian cancer, Premal Thaker, Melanie Bergman, and See all authors in comments
Critical appraisal of minimally invasive keyhole surgery for intracranial meningioma in a large case series., Jai Deep Thakur, Regin Jay Mallari, Alex Corlin, Samantha Yawitz, Amy Eisenberg, John Rhee, Walavan Sivakumar, Howard Krauss, Neil A Martin, Chester Griffiths, Garni Barkhoudarian, and Daniel F Kelly
409 Manufacturing of a clinical scale CD8 TIL product, AGX148, with and without gene silencing of PD-1 using self-delivering RNAi INTASYLTM PH-762, Colin Thalhofer, Tarsem Moudgil, Bernard A Fox, Nelson Sanjuan Silva, Eric Tran, and See all authors in comments
Enriching for tumor-reactive CD8 TIL (AGX148) leads to effective tumor clearance in a patient-derived xenograft model, C Thalhofer, Andrew D Weinberg, and See full list of authors in comments
Association of PD-L1 expression, tumor mutational burden and immunotherapy with venous thrombosis in patients with solid organ malignancies., Rajat Thawani, Thomas Kartika, Benjamin Elstrott, Elizabeth Batiuk, Derrick L Tao, Sonia Gowda, Lilian Chen, Corinne Lavasseur, Nattapron Tun, Nicholas F Taflin, and Joseph Shatzel
Outcomes of Therapies and Resistance Mutations Following Non-Covalent Bruton's Tyrosine Kinase Inhibitor Treatment for Patients with Chronic Lymphocytic Leukemia and Richter Transformation, Meghan C. Thompson, Krish Patel, Neil Bailey, and See all authors in comments
Circulating Tumor DNA Identifies Diverse Landscape of Acquired Resistance to Anti-Epidermal Growth Factor Receptor Therapy in Metastatic Colorectal Cancer., James T Topham, Chris J O'Callaghan, Harriet Feilotter, Hagen F Kennecke, Young S Lee, Weimin Li, Kimberly C Banks, Katie Quinn, Daniel J Renouf, Derek J Jonker, Dongsheng Tu, Eric X Chen, and Jonathan M Loree
Cell transfer therapy targeting mutated neoantigens in epithelial cancer, E Tran
Targeting mutant KRAS with adoptive T-cell therapy, E Tran
Targeting mutant KRAS with TCR-gene therapy, E Tran
TCR-gene therapy targeting mutant KRAS, E Tran
Targeting mutant KRAS with TCR-gene therapy, Eric Tran
TILs Update, Eric Tran
Neoantigen T-Cell Receptor Gene Therapy in Pancreatic Cancer. Reply., Eric Tran, Walter Urba, and Rom Leidner
Routine frozen section during pancreaticoduodenectomy does not improve value-based care, Abhineet Uppal, Wade O Christopher, Trang Nguyen, Brooke Vuong, Stacey Stern, Juan Mejia, Roshanthi Weerasinghe, Evan Ong, and Anton J Bilchik
The TARGIT-A Randomized Trial: TARGIT-IORT Versus Whole Breast Radiation Therapy: Long-Term Local Control and Survival., Jayant S Vaidya, Max Bulsara, Frederik Wenz, Elena Sperk, Samuele Massarut, Michael Alvarado, Norman R Williams, Chris Brew-Graves, Marcelle Bernstein, Dennis Holmes, Lorenzo Vinante, Steffi Pigorsch, Steinar Lundgren, Valery Uhl, David Joseph, Jeffrey S Tobias, and TARGIT-A authors
Editorial: Mechanisms of Lymphocyte Exclusion in the Tumor Microenvironment., Rieneke van de Ven, Carlo Bifulco, Jason J Luke, and Sarah E Church
Neoantigen-specific CD4 + T cells in human melanoma have diverse differentiation states and correlate with CD8 + T cell, macrophage, and B cell function, Joshua R Veatch, Sylvia M Lee, Carolyn Shasha, Naina Singhi, Julia L Szeto, Ata S Moshiri, Teresa S Kim, Kimberly Smythe, Paul Kong, Matthew Fitzgibbon, Brenda Jesernig, Shailender Bhatia, Scott S Tykodi, Evan T Hall, David R Byrd, John A Thompson, Venu G Pillarisetty, Thomas Duhen, A McGarry Houghton, Evan Newell, Raphael Gottardo, and Stanley R Riddell
Robotic vs laparoscopic nephroureterectomy for upper tract urothelial carcinoma: a multicenter propensity-score matched pair "tetrafecta" analysis (ROBUUST collaborative group)., Alessandro Veccia, Umberto Carbonara, Hooman Djaladat, Reza Mehrazin, Daniel Eun, Adam C Reese, Xiaosong Meng, Robert Uzzo, Abhishek Srivastava, James R Porter, Jason Farrow, Marcus Jamil, Giuseppe Rosiello, Riccardo Tellini, Andrea Mari, Ali Al-Qathani, Koon Ho Rha, Linhui Wang, Riccardo Mastroianni, Matteo Ferro, Ottavio De Cobelli, Kevin Hakimi, Fabio Crocerossa, Alireza Ghoreifi, Giovanni Cacciamani, Amit Amit S Bhattu, Alexandre Mottrie, Firas Abdollah, Andrea Minervini, Zhenjie Wu, Giuseppe Simone, Ithaar H Derweesh, Mark L Gonzalgo, Vitaly Margulis, Chandru P Sundaram, and Riccardo Autorino
CTNI-51. FEASIBILITY AND SAFETY OF NEUROSURGICAL RESECTION AND INTRA-OPERATIVE RADIATION THERAPY USING THE XOFT AXXENT ELECTRONIC BRACHYTHERAPY SYSTEM AND BEVACIZUMAB IN RECURRENT GLIOBLASTOMA, Naveed Wagle, Garni Barkhoudarian, Lisa Chaiken, Robert Wollman, Akanksha Sharma, Jose Carrillo, Minhdan Nguyen, Judy D Truong, Jared Chow, Emma Chacon, and Santosh Kesari
Geno4ME: establishment of an equitable whole-genome sequencing-based platform for clinical screening in a large healthcare system, Josiah Wagner, I A. Lucas-Beckett, K R. Emery, B A. Cosgrove, John T. Welle, K Jade, N D. Wagner, J Rinaldi, Lindsay Dickey, K G. Jones, L Yuan, E M. Shull, J Clemens, Keri Vartanian, A T. Magis, M B. Campbell, Brian Piening, Carlo Bifulco, and Ora K. Gordon
Clinical Performance of Comprehensive Genomic Profiling Using a Wide Range of Input Quantities and Solid Tumor Tissue Types, Josiah Wagner, S Reynolds, A Dowdell, E Shull, J Welle, M Pukay, R Rattray, C Moung-Wen, T Ward, M Campbell, C Bifulco, and B Piening
Novel Therapeutics and Treatment Strategies for Medullary Thyroid Cancer., Evan Walgama, Naifa Busaidy, and Mark Zafereo
Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study., Michael Wang, Javier Munoz, Andre Goy, Frederick L Locke, Caron A Jacobson, Brian T Hill, John M Timmerman, Houston Holmes, Samantha Jaglowski, Ian W Flinn, Peter A McSweeney, David B Miklos, John M Pagel, Marie José Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine R Shen, Rubina Siddiqi, Ioana Kloos, and Patrick M Reagan
Why so Shocky?? A case of refractory shock, Brittney Ward, Cicily Hummer, and Joseph Bell
Streamlining Solid Tumor Comprehensive Genomic Profiling Workflows Using Learned Variant and Sequencing Noise Autoclassification, Thomas Ward, S Reynolds, J Wagner, N Naidoo, E Shull, John Welle, R Rattray, C Moung-Wen, Mary Campbell, Brian Piening, and Carlo Bifulco
Identification of clinically actionable biomarkers via routine comprehensive genomic profiling across a large community health system, Roshanthi Weerasinghe, Ryan Meng, Alexa K Dowdell, Bela Bapat, Ann Vita, Brock Schroeder, Alisha Stein, Lauren Harold, Mark Schmidt, Shu-Ching Chang, Thomas R. Ward, Josiah T Wagner, Stanley Piotrowski, Phillip G. Febbo, Carlo Bifulco, and Brian D. Piening
Identification of clinically actionable biomarkers via routine comprehensive genomic profiling across a large community health system., Rosohanthi K. Weersinghe, Ryan Meng, Alexa K. Dowdell, Bela Bapat, Ann Vita, Brock Schroeder, Alisha Stein, Lauren Harold, Mark Schmidt, Shu-Ching Chang, Thomas Ward, Josiah Wagner, Stanley Piotrowski, Phillip G. Febbo, Carlo Bifulco, and Brian Piening
Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy., Joanne Weidhaas, Nicholas Marco, Aaron W Scheffler, Anusha Kalbasi, Kirk Wilenius, Emily Rietdorf, Jaya Mini Gill, Mara Heilig, Caroline Desler, Robert K Chin, Tania Kaprealian, Susan McCloskey, Ann Raldow, Naga P Raja, Santosh Kesari, Jose Carrillo, Alexandra Drakaki, Mark Scholz, and Donatello Telesca
Enriching for tumor-reactive CD8 TIL using CD39/103 markers: Clinical implications, A Weinberg
Isolating/Expanding the Entire TIL Repertoire of Tumor-Reactive CD8 T Cells for Cell Therapy in H&N Cancer, Andrew Weinberg
Identifying tumor-reactive CD8+ TIL in patients with solid malignancies: clinical implications, Andrew D Weinberg
T Cell Agonists, Andrew D Weinberg
Accepting social e-cigarette behaviors among fraternity members found utilizing egocentric network analysis, AC Welch, MS Patterson, CL Wilshire, H Kathuria, CR Gilbert, and JA Gorden
The role of ego networks for college fraternity members who use e-cigarettes, AC Welch, MS Patterson, CL Wilshire, H Kathuria, CR Gilbert, and JA Gorden
Design and Validation of a Whole-Genome SequencingBased Assay for Population Health, John Welle, Brian Piening, Josiah Wagner, I Lucas-Beckett, Thomas Ward, B Cosgrove, Eric Shull, R Rattray, Marina Pukay, Milena Ricks, K Childers, J Linehan, M Campbell, Ora Gordon, and Carlo Bifulco
Adipocytes Encapsulating Telratolimod Recruit and Polarize Tumor-Associated Macrophages for Cancer Immunotherapy., Di Wen, Tingxizi Liang, Guojun Chen, Hongjun Li, Zejun Wang, Jinqiang Wang, Ruxing Fu, Xiao Han, Tianyuan Ci, Yuqi Zhang, Peter Abdou, Ruoxin Li, Linlin Bu, Gianpietro Dotti, and Zhen Gu
778 Botensilimab, a novel innate/adaptive immune activator, plus or minus balstilimab (anti-PD-1) in “cold” and I-O refractory metastatic solid tumors, Breelyn Wilky, Kim Margolin, Rachel E Sanborn, Steven O'Day, and See full list of authors in comments
Comparing Initial Surgery versus Fibrinolytics for Pleural Space Infections: A Retrospective Multicenter Cohort Study., Candice Wilshire, Anee Sophia Jackson, Austin M Meggyesy, Kerrie E Buehler, Shu-Ching Chang, Leah C Horslen, Joshua R Rayburn, Carson C Fuller, Alexander S Farivar, Adam J Bograd, Brian Louie, Eric Vallieres, Ralph W Aye, Christopher R Gilbert, and Jed A Gorden
Lower paraspinous muscle index at first thoracentesis is associated with poor survival in non-small cell lung cancer, CL Wilshire, AM Meggyesy, JA Gorden, and CR Gilbert
Early experience with UGN-101 for the treatment of upper tract urothelial cancer - A multicenter evaluation of practice patterns and outcomes., Solomon L Woldu, Craig Labbate, Katie S Murray, Kyle Rose, Wade Sexton, Isamu Tachibana, Hristos Kaimakliotis, Joseph Jacob, Rian Dickstein, Jennifer Linehan, Alan Nieder, Marc A Bjurlin, Mitchell Humphreys, Saum Ghodoussipor, Marcus L Quek, Michael O'Donnell, Brian H Eisner, Adam S Feldman, Surena F Matin, and Yair Lotan
Current Clinical Trial Landscape of OX40 Agonists., Rashi Yadav and William L. Redmond
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial., Tomoko Yamazaki, Andrew J Gunderson, Miranda Gilchrist, Mark Whiteford, Maria X Kiely, Amanda Hayman, David O'Brien, Rehan Ahmad, Jeffrey V Manchio, Nathaniel E Fox, Kayla McCarty, Michaela Phillips, Evelyn Brosnan, Gina Vaccaro, Rui Li, Miklos Simon, Eric Bernstein, Mary McCormick, Lena Yamasaki, Yaping Wu, Ashley Drokin, Trevor Carnahan, Yy To, William L. Redmond, Brian Lee, Jeannie Louie, Eric Hansen, Matthew C Solhjem, Julie Cramer, Walter Urba, Michael J. Gough, Marka R Crittenden, and Kristina H Young
Nivolumab Plus Cabozantinib With or Without Ipilimumab for Advanced Hepatocellular Carcinoma: Results From Cohort 6 of the CheckMate 040 Trial., Thomas Yau, Vittorina Zagonel, Armando Santoro, Mirelis Acosta-Rivera, Su Pin Choo, Ana Matilla, Aiwu Ruth He, Antonio Cubillo Gracian, Anthony B El-Khoueiry, Bruno Sangro, Tarek E Eldawy, Jordi Bruix, Giovanni Luca Frassineti, Gina Vaccaro, Marina Tschaika, Christian Scheffold, Petra Koopmans, Jaclyn Neely, and Fabio Piscaglia
Daratumumab, cyclophosphamide, bortezomib, and dexamethasone for multiple myeloma: final results of the LYRA study., Habte Yimer, Jason Melear, Edward Faber, William Bensinger, John M Burke, Mohit Narang, Don Stevens, Kathleen S Gray, Yana Lutska, Padma Bobba, Keqin Qi, Daniela Hoehn, Ming Qi, Thomas S Lin, and Robert M Rifkin
The landscape of brain tumor mimics in neuro-oncology practice., Lalanthica V Yogendran, Tuba Kalelioglu, Joseph H Donahue, Haroon Ahmad, Kester A Phillips, Nicole M Calautti, Maria-Beatriz Lopes, Ashok R Asthagiri, Benjamin Purow, David Schiff, Sohil H Patel, and Camilo E Fadul
Identification of Patients With Ovarian Cancer Experiencing the Highest Benefit From Bevacizumab in the First-Line Setting on the Basis of Their Tumor-Intrinsic Chemosensitivity (KELIM): The GOG-0218 Validation Study., Benoit You, Christopher Purdy, Larry J Copeland, Elizabeth M Swisher, Michael A Bookman, Gini Fleming, Robert Coleman, Leslie M Randall, Krishnansu S Tewari, Bradley J Monk, Robert S Mannel, Joan L Walker, Fabio Cappuccini, David Cohn, Mahvish Muzaffar, David Mutch, Andrea Wahner-Hendrickson, Lainie Martin, Olivier Colomban, and Robert A Burger
A phase II trial of TGFβ type I receptor inhibitor, galunisertib, plus neoadjuvant chemoradiation in patients with locally advanced rectal cancer., Kristina H Young, Walter Urba, Michael J. Gough, Marka R Crittenden, and See full list of authors in comments
Surgical approach to pediatric mediastinal masses based on imaging characteristics., Stephanie Young, R Luke Rettig, Ian V Hutchinson, Michael G Sutcliffe, and Roman M Sydorak
1171 CAN1012: a selective and potent TLR7 agonist with strong antitumoral properties mediated by localized innate immune activation, Henry Yu, William L. Redmond, Yoshinobu Koguchi, and See all authors in comments
Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancers., Chunhong Zheng, Joseph N Fass, Yi-Ping Shih, Andrew J Gunderson, Nelson Sanjuan Silva, Huayu Huang, Brady M Bernard, Venkatesh Rajamanickam, Joseph Slagel, Carlo B Bifulco, Brian Piening, Pippa H A Newell, Paul D Hansen, and Eric Tran
Submissions from 2021
Transition Therapy: Tackling the Ecology of Tumor Phenotypic Plasticity., Guim Aguadé-Gorgorió, Stuart Kauffman, and Ricard Solé
Phase 1b dose-escalation study of the selective, noncovalent, reversible Bruton's tyrosine kinase inhibitor vecabrutinib in B-cell malignancies., John N Allan, Javier Pinilla-Ibarz, Douglas E Gladstone, Krish Patel, Jeff P Sharman, William G Wierda, Michael Y Choi, Susan M O'Brien, Mazyar Shadman, Matthew S Davids, John M Pagel, Habte A Yimer, Renee Ward, Gary Acton, Pietro Taverna, Daniel L Combs, Judith A Fox, Richard R Furman, and Jennifer R Brown
The American Society of Pain and Neuroscience (ASPN) Best Practices and Guidelines for the Interventional Management of Cancer-Associated Pain., Mansoor M Aman, Ammar Mahmoud, Timothy Deer, Dawood Sayed, Jonathan M Hagedorn, Shane E Brogan, Vinita Singh, Amitabh Gulati, Natalie Strand, Jacqueline Weisbein, Johnathan H Goree, Fangfang Xing, Ali Valimahomed, Daniel J Pak, Antonios El Helou, Priyanka Ghosh, Krishna Shah, Vishal Patel, Alexander Escobar, Keith Schmidt, Jay Shah, Vishal Varshney, William Rosenberg, and Sanjeet Narang
Minimal Residual Disease in Myeloma: Application for Clinical Care and New Drug Registration., Kenneth C Anderson, Daniel Auclair, Stacey J Adam, Amit Agarwal, Melissa Anderson, Herve Avet-Loiseau, Mark Bustoros, Jessica Chapman, Dana E Connors, Ajeeta Dash, Alessandra Di Bacco, Ling Du, Thierry Facon, Juan Flores-Montero, Francesca Gay, Irene M Ghobrial, Nicole J Gormley, Ira Gupta, Howard Higley, Jens Hillengass, Bindu Kanapuru, Dickran Kazandjian, Gary J Kelloff, Ilan R Kirsch, Brandon E Kremer, Ola Landgren, Elizabeth D Lightbody, Oliver C Lomas, Sagar Lonial, Maria Victoria Mateos, Rocio Montes de Oca, Lata Mukundan, Nikhil C Munshi, Elizabeth K O'Donnell, Alberto Orfao, Bruno Paiva, Reshma Patel, Trevor J Pugh, Karthik Ramasamy, Jill Ray, Mikhail Roshal, Jeremy A Ross, Caroline C Sigman, Katie L Thoren, Suzanne Trudel, Gary A Ulaner, Nancy Valente, Brendan M Weiss, Elena Zamagni, and Shaji K Kumar
Persistent N2 Following Induction Is Not a Contraindication to Surgery for Lung Cancer., Weston G Andrews, Brian Louie, Massimo Castiglioni, Ankit Dhamija, Alexander S Farivar, Joshua Chansky, Peter T White, Ralph W Aye, Eric Vallieres, and Adam J Bograd
Implications of Adverse Biological Factors and Management of Solitary Fibrous Tumors of the Pleura., Weston G Andrews and Eric Vallières
Clinical Responses of Oncolytic Coxsackievirus A21 (V937) in Patients With Unresectable Melanoma., Robert H I Andtbacka, Brendan Curti, Gregory A Daniels, Sigrun Hallmeyer, Eric D Whitman, Jose Lutzky, Lynn E Spitler, Karl Zhou, Praveen K Bommareddy, Mark Grose, Meihua Wang, Cai Wu, and Howard L Kaufman
Utilizing an interim futility analysis of the OVAL study (VB-111-701/GOG 3018) for potential reduction of risk: A phase III, double blind, randomized controlled trial of ofranergene obadenovec (VB-111) and weekly paclitaxel in patients with platinum resistant ovarian cancer., Rebecca C Arend, Bradley J Monk, Thomas J Herzog, Kathleen N Moore, Ronnie Shapira-Frommer, Jonathan A Ledermann, Krishnansu S Tewari, Angeles Alvarez Secord, Tamar Rachmilewitz Minei, Laurence S Freedman, Austin Miller, Shifra Fain Shmueli, Michal Lavi, and Richard T Penson
iNetModels 2.0: an interactive visualization and database of multi-omics data., Muhammad Arif, Cheng Zhang, Xiangyu Li, Cem Güngör, Buğra Çakmak, Metin Arslantürk, Abdellah Tebani, Berkay Özcan, Oğuzhan Subaş, Wenyu Zhou, Brian Piening, Hasan Turkez, Linn Fagerberg, Nathan Price, Leroy Hood, Michael Snyder, Jens Nielsen, Mathias Uhlen, and Adil Mardinoglu
Perspectives in immunotherapy: meeting report from the immunotherapy bridge (December 2nd-3rd, 2020, Italy)., Paolo A Ascierto, Carlo Bifulco, Fortunato Ciardiello, Sandra Demaria, Leisha A Emens, Robert Ferris, Silvia C Formenti, Jerome Galon, Samir N Khleif, Tomas Kirchhoff, Jennifer McQuade, Kunle Odunsi, Akash Patnaik, Chrystal M Paulos, Janis M Taube, John Timmerman, Bernard A Fox, Patrick Hwu, and Igor Puzanov
Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 3rd-5th, 2020, Italy)., Paolo A Ascierto, Christian Blank, Reinhard Dummer, Marc S Ernstoff, Soldano Ferrone, Bernard A Fox, Thomas F Gajewski, Claus Garbe, Patrick Hwu, Pawel Kalinski, Michelle Krogsgaard, Roger S Lo, Jason J Luke, Bart Neyns, Michael A Postow, Sergio A Quezada, Michele W L Teng, Giorgio Trinchieri, Alessandro Testori, Corrado Caracò, Iman Osman, Igor Puzanov, and Magdalena Thurin
The "Great Debate" at Immunotherapy Bridge 2020, December 3rd, 2020., Paolo A Ascierto, Joshua Brody, Lisa H Butterfield, Olivera J Finn, John Goldberg, Francesco Perrone, Ryan J Sullivan, Bernard A Fox, Patrick Hwu, and Igor Puzanov
The State of Melanoma: Emergent Challenges and Opportunities., Michael B Atkins, Clara Curiel-Lewandrowski, David E Fisher, Susan M Swetter, Hensin Tsao, Julio A Aguirre-Ghiso, Maria S Soengas, Ashani T Weeraratna, Keith T Flaherty, Meenhard Herlyn, Jeffrey A Sosman, Hussein A Tawbi, Anna C Pavlick, Pamela B Cassidy, Sunandana Chandra, Paul B Chapman, Adil Daud, Zeynep Eroglu, Laura K Ferris, Bernard A Fox, Jeffrey E Gerhsenwald, Geoffrey T Gibney, Douglas Grossman, Brent A Hanks, Douglas Hanniford, Eva Hernando, Joanne M Jeter, Douglas B Johnson, Samir N Khleif, John M Kirkwood, Sancy A Leachman, Darren Mays, Kelly C Nelson, Vernon K Sondak, Ryan J Sullivan, and Glenn Merlino
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing): A phase III trial—ECOG-ACRIN EA6134, Michael B. Atkins, Brendan Curti, and See full list of authors in comments
Phase I Trial of Cemiplimab, Radiotherapy, Cyclophosphamide, and Granulocyte Macrophage Colony-Stimulating Factor in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma., Hani Babiker, Irene Brana, Daruka Mahadevan, Taofeek Owonikoko, Emiliano Calvo, Danny Rischin, Victor Moreno, Kyriakos P Papadopoulos, Marka Crittenden, Silvia Formenti, Jordi Giralt, Pilar Garrido, Ainara Soria, Asunción Hervás-Morón, Kosalai Kal Mohan, Matthew Fury, Israel Lowy, Melissa Mathias, Minjie Feng, Jingjin Li, and Elizabeth Stankevich
Arginase therapy combines effectively with checkpoint blockade or agonist anti-OX40 immunotherapy to control tumor growth., Mark D Badeaux, Annah S Rolig, Giulia Agnello, Danlee Enzler, Melissa Kasiewicz, Leslie Priddy, Jason F Wiggins, Alexander Muir, Mark R Sullivan, Jessica Van Cleef, Christopher Daige, Matthew G Vander Heiden, Venkatesh Rajamanickam, James Wooldridge, William L. Redmond, and Scott W Rowlinson
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy, Keith Sadoon Bahjat, Helena Maria Hoen, Yoshinobu Koguchi, and Alan J. Korman
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy, Keith Sandoon Bahjat, Helena Maria Hoen, Yoshinobu Koguchi, and Alan J. Korman
Initial Safety Results from a Phase II Study of Acalabrutinib Plus RICE Followed By Autologous Hematopoietic Cell Transplantation and/or Acalabrutinib Maintenance Therapy for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Neil Bailey, Tenzin Tsomo, Tori Braun, Jennie Szeto, William Bensinger, Daniel N Egan, Raya Mawad, Livia Hegerova, Gayle Funk, Joanna Fesler, Megumi Bailey, John M Pagel, and Krish Patel
Immune-based mutation classification enables neoantigen prioritization and immune feature discovery in cancer immunotherapy., Peng Bai, Yongzheng Li, Qiuping Zhou, Jiaqi Xia, Peng-Cheng Wei, Hexiang Deng, Min Wu, Sanny K Chan, John W Kappler, Yu Zhou, Eric Tran, Philippa Marrack, and Lei Yin
Prevalence and Correlates of Successful Smoking Cessation in Bladder Cancer Survivors., Jeffrey C Bassett, Richard S Matulewicz, Lorna Kwan, William J McCarthy, John L Gore, and Christopher S Saigal
A national database propensity score-matched comparison of minimally invasive and open colectomy for long-term opioid use., Amir L Bastawrous, Kara K Brockhaus, Melissa I Chang, Gediwon Milky, I-Fan Shih, Yanli Li, and Robert K Cleary
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response., Joshua Bauml, Byoung Chul Cho, Rachel E Sanborn, and See full author list in comments
Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update., Nancy N Baxter, Erin B Kennedy, Emily Bergsland, Jordan Berlin, Thomas J George, Sharlene Gill, Philip J Gold, Alex Hantel, Lee Jones, Christopher Lieu, Najjia Mahmoud, Arden M Morris, Erika Ruiz-Garcia, Y Nancy You, and Jeffrey A Meyerhardt
Identifying breast cancer recurrence histories via patient-reported outcomes., J David Beatty, Qin Sun, Daniel Markowitz, Jessica Chubak, Bin Huang, and Ruth Etzioni
The miR-181a-SFRP4 axis regulates Wnt activation to drive stemness and platinum resistance in ovarian cancer., Anil Belur Nagaraj, Matthew Knarr, Sreeja Sekhar, R Shae Connor, Peronne Joseph, Olga Kovalenko, Alexis Fleming, Arshia Surti, Elmar Nurmemmedov, Luca Beltrame, Sergio Marchini, Michael Kahn, and Analisa DiFeo
The virtual molecular tumor board as a tool for the delivery of precision oncology, Carlo Bifulco
10. Dendritic cell migration is required for the immunological responsiveness of tumors to radiation therapy, TC Blair, G Kramer, S Bambina, A Dowdell, AF Alice, Brian D. Piening, Marka R Crittenden, and MJ Gough
Minimally invasive esophagectomy., Adam J Bograd and Daniela Molena
Salvage Pulmonary Resections After Definitive Chemoradiotherapy., Adam J Bograd and Eric Vallieres
DNA Damage Response in Glioblastoma: Mechanism for Treatment Resistance and Emerging Therapeutic Strategies., Alipi Bonm and Santosh Kesari
Marizomib alone or in combination with bevacizumab in patients with recurrent glioblastoma: Phase I/II clinical trial data., Daniela A Bota, Warren Mason, Santosh Kesari, Rajiv Magge, Benjamin Winograd, Ileana Elias, Steven D Reich, Nancy Levin, Mohit Trikha, and Annick Desjardins
